The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
about
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysisModeling Outcomes of First-Line Antiretroviral Therapy and Rate of CD4 Counts Change among a Cohort of HIV/AIDS Patients in Ethiopia: A Retrospective Cohort StudyApplication of marginal structural models in pharmacoepidemiologic studies: a systematic review.Factors associated with remaining on initial randomized efavirenz-containing regimens.The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region.Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
P2860
Q27021762-2EA553F4-F4E6-40D9-A94B-423AA9D81A7EQ28555157-CB881F7F-AD8E-474D-B0FE-F7D512D460E9Q33707284-A98F6CE2-649D-4F4E-BA1F-1F3BA53C0387Q34378368-7AFCD955-0EA2-470E-94E9-3CAAB2BB5CD1Q34433397-231E3051-C136-4928-A9A6-3A1499915A5AQ34571594-9C14CB6D-A83C-48CC-8C4B-A459AD7EB031Q35014739-B582393E-2E99-4889-B6BA-ADDDEB61D773Q35149749-51EF2C10-B49E-45F3-90B5-F988AF8CFF33Q35539510-F0A2FAB1-1A4D-464B-90BA-A8A1E0082BEEQ35930384-A27B311B-0281-4A9C-9784-1B5C4A4F3736Q37019021-B62B66AB-5A25-4124-9FF0-02E4E13744CFQ37354847-3D5C0C4B-CA4D-4889-A590-E1746B65DEB9Q37732266-A6BCE6CC-742A-4B82-BB73-B6E0FBE64647
P2860
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The effect of efavirenz versus ...... ospective observational study.
@ast
The effect of efavirenz versus ...... ospective observational study.
@en
The effect of efavirenz versus ...... ospective observational study.
@nl
type
label
The effect of efavirenz versus ...... ospective observational study.
@ast
The effect of efavirenz versus ...... ospective observational study.
@en
The effect of efavirenz versus ...... ospective observational study.
@nl
prefLabel
The effect of efavirenz versus ...... ospective observational study.
@ast
The effect of efavirenz versus ...... ospective observational study.
@en
The effect of efavirenz versus ...... ospective observational study.
@nl
P2093
P2860
P50
P1433
P1476
The effect of efavirenz versus ...... ospective observational study.
@en
P2093
Amy Justice
Andrew Phillips
Anna Esteve
Frank de Wolf
Georgia Vourli
Giota Touloumi
HIV-CAUSAL Collaboration
Heiner C Bucher
James M Robins
Janet Tate
P2860
P304
P356
10.1097/QAD.0B013E328354F497
P407
P577
2012-08-01T00:00:00Z